Following our recent coverage of the new US tariffs on pharmaceutical imports, it is worth noting that Europe is also seeing significant regulatory shifts affecting the pharmaceutical sector. France has introduced a new tax targeting pharmaceutical companies whose patent strategies are deemed to unjustifiably delay the market entry of generic medicines by more than one year beyond patent expiry. The tax is set at 3% of French turnover from the relevant product, rising to 5% for repeat offences. 

 

Read the full article on Patent Hub here.